Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation.
METex14del
lung adenocarcinoma
osimertinib
resistance
tepotinib
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
06
2022
accepted:
30
09
2022
entrez:
31
10
2022
pubmed:
1
11
2022
medline:
1
11
2022
Statut:
epublish
Résumé
Osimertinib is a standard therapy for the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor gene (
Identifiants
pubmed: 36313664
doi: 10.3389/fonc.2022.965741
pmc: PMC9608750
doi:
Types de publication
Case Reports
Langues
eng
Pagination
965741Informations de copyright
Copyright © 2022 Takamori, Seto, Yamaguchi, Kinoshita, Fujishita, Ito, Toyozawa, Shoji and Okamoto.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Curr Treat Options Oncol. 2020 Apr 18;21(4):33
pubmed: 32306194
Lung Cancer (Auckl). 2022 May 13;13:33-45
pubmed: 35592355
Ann Oncol. 2020 Apr;31(4):507-516
pubmed: 32139298
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
J Clin Oncol. 2020 Jun 18;:JCO1903123
pubmed: 32552277
Clin Lung Cancer. 2022 Mar;23(2):e131-e134
pubmed: 34548228
J Thorac Oncol. 2017 Jun;12(6):963-973
pubmed: 28189832
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
Lancet Oncol. 2020 Mar;21(3):373-386
pubmed: 32027846
JCO Precis Oncol. 2019;3:
pubmed: 31157314